

NYMU in Taiwan collaborates with US firm

20 August 2020 | News

For diagnosis and monitoring treatment outcomes of neurological disorders



US based Vyripharm International has executed a memorandum of understanding (MoU) with National Yang-Ming University (NYMU), a research institution in Taipei, Taiwan.

NYMU is famous for its research in medicine, life sciences and biotechnology. The MoU expresses the intent to develop the bio-distribution information and targeting profile of VYR-206 for diagnosis and monitoring treatment outcomes of neurological disorders.

NYMU's Brain Research Center and Translational Medical Imaging Center is one of the leading institutes in cognition and behavioral research along with functional and structural brain imaging.

Vyripharm's drug platform technology is a personalized medicine application for diagnosis, monitoring and treatment of some infectious diseases, neurological disorders and cancers. Moreover, the platform provides a means for labeling diagnostic and therapeutic agents to allow for tissue specific targeted diagnostic imaging and radiotherapy.

The company developed VYR-206 as one of its lead compounds from several of its platforms for both proof of concepts and commercialization development.